v3.3.1.900
Segments of Business and Geographic Areas (Details 5) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2016
 [1]
Sep. 27, 2015
 [2]
Jun. 28, 2015
 [3]
Mar. 29, 2015
 [4]
Dec. 28, 2014
 [5]
Sep. 28, 2014
 [6]
Jun. 29, 2014
 [7]
Mar. 30, 2014
 [8]
Jan. 03, 2016
Dec. 28, 2014
Dec. 29, 2013
Sales by geographic area                      
Total $ 17,811 $ 17,102 $ 17,787 $ 17,374 $ 18,254 $ 18,467 $ 19,495 $ 18,115 $ 70,074 $ 74,331 $ 71,312
Operating Segments [Member]                      
Sales by geographic area                      
Total                 $ 70,074 $ 74,331 $ 71,312
[1] The fourth quarter of 2015 includes a restructuring charge of $415 million after-tax ($590 million before-tax), $156 million after-tax ($214 million before-tax) from impairment of in-process research and development and Synthes integration costs of $59 million after-tax ($83 million before-tax). Additionally, the fourth quarter of 2015 includes the gain on the Cordis divestiture.
[2] The third quarter of 2015 includes net litigation expense of $348 million after-tax ($409 million before-tax).
[3] The second quarter of 2015 includes net litigation expense of $23 million after-tax ($134 million before-tax).
[4] The first quarter of 2015 includes a net litigation gain of $253 million after-tax ($402 million before-tax) and $122 million after-tax ($139 million before-tax) for costs associated with the DePuy ASRTM Hip program.
[5] The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[6] The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[7] The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[8] The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.